HomeCompareCRGX vs PM

CRGX vs PM: Dividend Comparison 2026

CRGX yields 44.74% · PM yields 3.48%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CRGX wins by $249.7K in total portfolio value
10 years
CRGX
CRGX
● Live price
44.74%
Share price
$4.47
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$299.2K
Annual income
$55,447.86
Full CRGX calculator →
PM
Philip Morris International
● Live price
3.48%
Share price
$165.34
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,492.02
Full PM calculator →

Portfolio growth — CRGX vs PM

📍 CRGX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCRGXPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CRGX + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CRGX pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CRGX
Annual income on $10K today (after 15% tax)
$3,803.13/yr
After 10yr DRIP, annual income (after tax)
$47,130.68/yr
PM
Annual income on $10K today (after 15% tax)
$296.12/yr
After 10yr DRIP, annual income (after tax)
$2,118.22/yr
At 15% tax rate, CRGX beats the other by $45,012.46/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CRGX + PM for your $10,000?

CRGX: 50%PM: 50%
100% PM50/50100% CRGX
Portfolio after 10yr
$174.4K
Annual income
$28,969.94/yr
Blended yield
16.61%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

CRGX
Analyst Ratings
6
Hold
1
Sell
Consensus: Hold
Price Target
$23.00
+414.5% upside vs current
Range: $7.00 — $34.00
Altman Z
3.1
Piotroski
2/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.5% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CRGX buys
0
PM buys
0
No recent congressional trades found for CRGX or PM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCRGXPM
Forward yield44.74%3.48%
Annual dividend / share$2.00$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17.2%
Portfolio after 10y$299.2K$49.6K
Annual income after 10y$55,447.86$2,492.02
Total dividends collected$232.3K$11.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy
Analyst price target$23.00$194.30

Year-by-year: CRGX vs PM ($10,000, DRIP)

YearCRGX PortfolioCRGX Income/yrPM PortfolioPM Income/yrGap
1← crossover$15,174$4,474.27$11,648$408.29+$3.5KCRGX
2$22,582$6,345.22$13,589$495.90+$9.0KCRGX
3$32,987$8,824.93$15,877$603.21+$17.1KCRGX
4$47,345$12,048.10$18,580$734.88+$28.8KCRGX
5$66,819$16,160.60$21,781$896.75+$45.0KCRGX
6$92,813$21,315.98$25,578$1,096.12+$67.2KCRGX
7$126,981$27,671.12$30,092$1,342.17+$96.9KCRGX
8$171,251$35,381.27$35,470$1,646.46+$135.8KCRGX
9$227,833$44,594.79$41,892$2,023.58+$185.9KCRGX
10$299,229$55,447.86$49,578$2,492.02+$249.7KCRGX

CRGX vs PM: Complete Analysis 2026

CRGXStock

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

Full CRGX Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this CRGX vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CRGX vs SCHDCRGX vs JEPICRGX vs OCRGX vs KOCRGX vs MAINCRGX vs MOCRGX vs BTICRGX vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.